Alchemab Therapeutics Raises Series A Financing Extension

ATLX-1282 was licensed to Eli Lilly and Company (Lilly) in May 2025 under an exclusive global agreement, which included a milestone payment to Alchemab upon Phase 1 initiation. Alchemab will run the Phase 1 study, while Lilly will handle further development and commercialization.

The company also raised $32 million in Series A extension funding, bringing total Series A investment to $114 million. Investors include Ono Venture Investment (OVI), existing investors RA Capital, SV Health Investors, DCVC Bio, Lightstone Ventures, and strategic investment from Lilly.

Read Also - Paris-based SafeHeal Raises $10M Series C Extension Funding

“As a founding investor in Alchemab, we are thrilled to close this financing and initiate clinical development, which together mark a very successful year for Alchemab and the Company’s novel platform to identify protective auto-antibodies,” said Kate Bingham, Alchemab Chair and SV Health Investors Managing Partner. “We’re extremely pleased to welcome new investors who share our commitment to novel drug discovery and development approaches and are proud to support Alchemab’s continued progress.”

Led by CEO Jane Osbourn, Alchemab studies the natural antibody responses of people who are highly resilient to disease. The company identifies antibodies found only in these resilient individuals and not in disease sufferers. These antibodies are then developed into therapies for hard-to-treat diseases that currently lack effective treatments.

Alchemab’s platform combines data mining and machine learning of patient immune responses with lab-based drug discovery to understand what keeps people healthy.

Jane Osbourn, Co-Founder and Chief Executive Officer, Alchemab, commented: “Reaching the key milestone of our first drug candidate into the clinic is great validation of Alchemab and our AI enabled next generation antibody platform. Through our collaboration with Lilly, we hope to get this, our first clinical candidate and a potentially transformative therapy, to as many patients as possible, as quickly as possible.”

Mike Hutton, Senior Vice President, Genetic Medicines and Neurodegeneration at Lilly, commented: “I am excited about the rapid progress we have made with this candidate as part of a joint team effort with Alchemab and look forward to seeing its performance in the clinic.”

About Alchemab

Founded in 2019, Alchemab studies antibodies in individuals naturally resilient to disease, identifying unique targets unseen in patients. Using data mining, machine learning and lab-based drug discovery, the company develops therapies for hard-to-treat diseases, aiming to harness the human immune system for breakthrough treatments. Headquartered in London, with labs in Cambridge.